Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions

Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to $380 million, to strengthen its position in ... Read More